leisure time -WSS

leisure time

author：explore 2025-09-30 00:45:21 - browse：42894

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： H5N1 bird flu outbreak: Second human case reported, in Michigan

WSS

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Making the case for fair compensation in clinical trials

ASCO eve: Let’s set the table for this year's meeting

Alabama frozen embryo ruling has major implications for IVF clinics

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

6 phony surgeries that take placebo to the extreme

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Investigation reveals sickle cell patients pressured into sterilizations

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA poised to publish guidelines for clinical trial diversity

Medicare details structure of new drug price negotiation program

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Digital health: a case of mistaken identity

focus

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

STAT readers on older presidents, polypills, Medicare, and more

Liver decline slowed by off

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

focus

hotspot

knowledge

leisure time